These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38602501)

  • 1. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
    Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
    J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma: A Multi-institutional Study.
    Agarwal S; Jung CK; Gaddam P; Hirokawa M; Higashiyama T; Hang JF; Lai WA; Keelawat S; Liu Z; Na HY; Park SY; Fukuoka J; Satoh S; Mussazhanova Z; Nakashima M; Kakudo K; Bychkov A
    Am J Surg Pathol; 2024 Oct; 48(10):1233-1244. PubMed ID: 39004795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B; Ghossein R
    Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
    J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
    Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
    Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
    Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
    J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
    Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
    Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas.
    Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
    Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of
    Murugan AK; Qasem E; Al-Hindi H; Alzahrani AS
    Mol Clin Oncol; 2021 Oct; 15(4):210. PubMed ID: 34462665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.
    Pita JM; Figueiredo IF; Moura MM; Leite V; Cavaco BM
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E497-507. PubMed ID: 24423316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
    Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
    Iñiguez-Ariza NM; Jasim S; Ryder MM; Chintakuntlawar AV; Morris JC; Hilger CR; Menefee ME; Smallridge RC; Karlin NJ; Alcaino C; Bible KC
    J Clin Endocrinol Metab; 2020 Jul; 105(7):e2346-57. PubMed ID: 32421817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
    Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
    Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
    [No Abstract]   [Full Text] [Related]  

  • 18. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
    Romei C; Elisei R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 20. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
    Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
    BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.